Overview

Ribavirin 200 mg Tablets Under Fasting Conditions

Status:
Completed

Trial end date:
2003-10-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of COPEGUS™ 200 mg tablets (Roche) in healthy, adult, non-smoking, females (who are unable to become pregnant) under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Pharmaceuticals USA

Treatments:

Ribavirin